Utilizing liposomal encapsulation approach to address nephrotoxic challenges of colistimethate sodium through a preclinical study

Simple item page
dc.contributor.authorRaktham Mektrirat
dc.contributor.authorNoppanut Paengjun
dc.contributor.authorPeerawit Chongrattanameteekul
dc.contributor.authorSonthaya Umsumarng
dc.contributor.authorSuppara Cheunsri
dc.contributor.authorKornravee Photichai
dc.contributor.authorKittima Lewchalermvong
dc.contributor.authorChalutwan Sansamur
dc.contributor.authorSiriporn Okonogi
dc.contributor.authorWasan Katip
dc.date.accessioned2026-05-08T19:16:29Z
dc.date.issued2023-11-22
dc.description.abstractcells/mL). Our study findings enhance the understanding of the safety profile of CL and its potential to improve patient outcomes through the use of liposomal colistin medication. Additional clinical studies are necessary to establish the optimal safety regiment in humans.
dc.identifier.doi10.3389/fphar.2023.1282464
dc.identifier.urihttps://dspace.kmitl.ac.th/handle/123456789/15551
dc.publisherFrontiers in Pharmacology
dc.subjectAntibiotic Resistance in Bacteria
dc.subjectUrinary Tract Infections Management
dc.subjectAntibiotics Pharmacokinetics and Efficacy
dc.titleUtilizing liposomal encapsulation approach to address nephrotoxic challenges of colistimethate sodium through a preclinical study
dc.typeArticle

Files

Collections

All